biotech · Alzheimer Disease · ABOS
Acumen Pharmaceuticals
Acumen Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 66
- Programs
- 4
- Drugs
- 9
- Patents
- 6
Acumen Pharmaceuticals projects
4 ClinicalTrials.gov programs sponsored by Acumen Pharmaceuticals.
Acumen Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ACU193-201
Acumen Pharmaceuticals
Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
1 trial -
sabirnetug
Acumen Pharmaceuticals
Alzheimer Disease
1 trial -
ACU193
Acumen Pharmaceuticals
Alzheimer Disease
1 trial -
sabirnetug (ACU193)
Acumen Pharmaceuticals
Alzheimer Disease
1 trial
Frequently asked questions
How many clinical projects does Acumen Pharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.